Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments
出版年份 2019 全文链接
标题
Routine sequencing in
CLL
has prognostic implications and provides new insight into pathogenesis and targeted treatments
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-03-29
DOI
10.1111/bjh.15877
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide
- (2018) Koichi Takahashi et al. BLOOD
- Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels
- (2018) Courtney D. DiNardo et al. CANCER
- Klhl6 Deficiency Impairs Transitional B Cell Survival and Differentiation
- (2017) Barbara Bertocci et al. JOURNAL OF IMMUNOLOGY
- Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia
- (2016) H. E. Speedy et al. BLOOD
- Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
- (2016) F. Nadeu et al. BLOOD
- Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
- (2016) C. D. Herling et al. BLOOD
- A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
- (2016) N. A. Amin et al. CLINICAL CANCER RESEARCH
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Prognostic relevance of MYD88 mutations in CLL: the jury is still out
- (2015) P. Baliakas et al. BLOOD
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
- (2015) Z. A. Hing et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
- (2015) Philip A. Thompson et al. CANCER
- Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer
- (2015) Xiaohong Wang et al. Gastric Cancer
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL
- (2015) Filomena De Falco et al. Oncotarget
- Splice-acceptor site mutation in p53 gene of hu888 zebrafish line
- (2014) Alicja Piasecka et al. JOURNAL OF APPLIED GENETICS
- The impact of SF3B1 mutations in CLL on the DNA-damage response
- (2014) G D te Raa et al. LEUKEMIA
- Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation
- (2014) F De Falco et al. LEUKEMIA
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- SF3B1 mutations in chronic lymphocytic leukemia
- (2013) Y. Wan et al. BLOOD
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort
- (2013) D Cortese et al. LEUKEMIA
- SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
- (2013) S Jeromin et al. LEUKEMIA
- POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia
- (2013) Andrew J Ramsay et al. NATURE GENETICS
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
- (2012) R. Lapalombella et al. BLOOD
- The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial
- (2012) D. G. Oscier et al. BLOOD
- Nuclear export of proteins and drug resistance in cancer
- (2011) Joel G. Turner et al. BIOCHEMICAL PHARMACOLOGY
- LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients
- (2011) H. Duzkale et al. BLOOD
- Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
- (2011) D. Rossi et al. BLOOD
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
- (2011) Víctor Quesada et al. NATURE GENETICS
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- A new genetic lesion in B-CLL: aNOTCH1PEST domain mutation
- (2009) Mauro Di Ianni et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started